Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2025)

Ocular Therapeutix has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at -$0.27 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.27 for Q4 2025, up 3.57% from a year ago — trailing twelve months through Dec 2025 was -$1.42 (down 13.6% YoY), and the annual figure for FY2025 was -$1.42, down 16.39%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.27 at Ocular Therapeutix, up from -$0.38 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for OCUL hit a ceiling of -$0.22 in Q1 2022 and a floor of -$0.49 in Q1 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.26 (2021), compared with a mean of -$0.29.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 82.84% in 2021 and later plummeted 77.27% in 2023.
  • Ocular Therapeutix's EPS (Weighted Average and Diluted) stood at -$0.23 in 2021, then dropped by 4.35% to -$0.24 in 2022, then decreased by 4.17% to -$0.25 in 2023, then fell by 12.0% to -$0.28 in 2024, then rose by 3.57% to -$0.27 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.27 (Q4 2025), -$0.38 (Q3 2025), and -$0.39 (Q2 2025) per Business Quant data.